Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPSTREAM in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT03088059Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2017
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 5
01
Overview
A Phase 2 trial of afatinib, palbociclib, niraparib, monalizumab, durvalumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2017; status: active, not recruiting.
02
Drugs
afatinibpalbociclibniraparibmonalizumabdurvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03088059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088059.